DE60219614T2 - 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes - Google Patents
3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes Download PDFInfo
- Publication number
- DE60219614T2 DE60219614T2 DE60219614T DE60219614T DE60219614T2 DE 60219614 T2 DE60219614 T2 DE 60219614T2 DE 60219614 T DE60219614 T DE 60219614T DE 60219614 T DE60219614 T DE 60219614T DE 60219614 T2 DE60219614 T2 DE 60219614T2
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- enyl
- oxocyclopentylsulfanyl
- propylsulfanyl
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 21
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 72
- -1 {3 - [(1R, 2S, 3R) -3-hydroxy-2 - ((S) - (E) -3-hydroxyoct-1-enyl) -5-oxocyclopentylsulfanyl] propylsulfanyl } isopropyl Chemical group 0.000 claims description 16
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- SHVVCUQPJHVSDK-NVUIJDHLSA-N 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid Chemical compound C(\[C@@H]1[C@H](C(=O)C[C@H]1O)SCCCSCC(O)=O)=C/CC(O)C1(CCC)CCC1 SHVVCUQPJHVSDK-NVUIJDHLSA-N 0.000 claims description 6
- 239000002997 ophthalmic solution Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 229940054534 ophthalmic solution Drugs 0.000 claims description 5
- IGDZTSSCEAWADH-MXZBKONQSA-N propan-2-yl 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetate Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1SCCCSCC(=O)OC(C)C IGDZTSSCEAWADH-MXZBKONQSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- WWLUQPFNSRRKNL-DVSAFCQGSA-N methyl 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetate Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1SCCCSCC(=O)OC WWLUQPFNSRRKNL-DVSAFCQGSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- NIEQXBMWWPPDER-ROUUACIJSA-N 6-[(1s,2s)-2-octylcyclopentyl]sulfanylhexanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1SCCCCCC(O)=O NIEQXBMWWPPDER-ROUUACIJSA-N 0.000 abstract description 3
- RZYCTWZLJOQWRN-ROUUACIJSA-N 5-[(1s,2s)-2-octylcyclopentyl]pentyl hydrogen carbonate Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCOC(O)=O RZYCTWZLJOQWRN-ROUUACIJSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 12
- 150000003180 prostaglandins Chemical class 0.000 description 12
- 230000004410 intraocular pressure Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- IWJGMNXHWPYORN-XPLDUGHQSA-N 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1SCCCSCC(O)=O IWJGMNXHWPYORN-XPLDUGHQSA-N 0.000 description 5
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000001077 hypotensive effect Effects 0.000 description 5
- JTYQLKRXGPRSDC-BMBBGFLSSA-N methyl 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetate Chemical compound C(\[C@@H]1[C@H](C(=O)C[C@H]1O)SCCCSCC(=O)OC)=C/CC(O)C1(CCC)CCC1 JTYQLKRXGPRSDC-BMBBGFLSSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BELZACNVMXNDHL-CYBMUJFWSA-N methyl 2-[3-[(3r)-3-[tert-butyl(dimethyl)silyl]oxy-5-oxocyclopenten-1-yl]sulfanylpropylsulfanyl]acetate Chemical compound COC(=O)CSCCCSC1=C[C@H](O[Si](C)(C)C(C)(C)C)CC1=O BELZACNVMXNDHL-CYBMUJFWSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KFTKJPWFFSOXRV-KYHHOPLUSA-N (1r)-4-[tert-butyl(dimethyl)silyl]oxy-6-oxabicyclo[3.1.0]hexan-2-one Chemical compound CC(C)(C)[Si](C)(C)OC1CC(=O)[C@@H]2OC12 KFTKJPWFFSOXRV-KYHHOPLUSA-N 0.000 description 3
- DAPZSGCXUJECAI-JTQLQIEISA-N (4r)-4-[tert-butyl(dimethyl)silyl]oxycyclopent-2-en-1-one Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]1CC(=O)C=C1 DAPZSGCXUJECAI-JTQLQIEISA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- NEWBNFQOFWWYHJ-AWIRGGBESA-N 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-3-hydroxy-4-phenylbut-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid Chemical compound C(\[C@@H]1[C@H](C(=O)C[C@H]1O)SCCCSCC(O)=O)=C/C(O)CC1=CC=CC=C1 NEWBNFQOFWWYHJ-AWIRGGBESA-N 0.000 description 2
- GMNIDEYMFBCVND-NHRLEUMJSA-N 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-3-hydroxy-4-phenylpent-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid Chemical compound C=1C=CC=CC=1C(C)C(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1SCCCSCC(O)=O GMNIDEYMFBCVND-NHRLEUMJSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- MFQCVLOXVMIEAR-NDXVEAPASA-N methyl 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-3-hydroxy-4-phenylbut-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetate Chemical compound O[C@@H]1CC(=O)[C@H](SCCCSCC(=O)OC)[C@H]1\C=C\C(O)CC1=CC=CC=C1 MFQCVLOXVMIEAR-NDXVEAPASA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LTLQAJZGKYDIDX-YLSINNKHSA-N tert-butyl-[(e,3s)-1-iodooct-1-en-3-yl]oxy-dimethylsilane Chemical compound CCCCC[C@@H](\C=C\I)O[Si](C)(C)C(C)(C)C LTLQAJZGKYDIDX-YLSINNKHSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VRSPJPYUHXNQHT-ZJUUUORDSA-N (1s,4r)-4-[tert-butyl(dimethyl)silyl]oxycyclopent-2-en-1-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]1C[C@H](O)C=C1 VRSPJPYUHXNQHT-ZJUUUORDSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- KNCQNMMWWSQZMW-IRXDYDNUSA-N 2-[3-[(1s,2s)-2-octylcyclopentyl]sulfanylpropylsulfanyl]acetic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1SCCCSCC(O)=O KNCQNMMWWSQZMW-IRXDYDNUSA-N 0.000 description 1
- KYPRFVQYVNECKT-ROUUACIJSA-N 2-[4-[(1R,2S)-2-octylcyclopentyl]butylsulfanyl]acetic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCSCC(O)=O KYPRFVQYVNECKT-ROUUACIJSA-N 0.000 description 1
- AGDYKCPGMDASQO-UHFFFAOYSA-N 4-methyl-n-(propan-2-yldiazenyl)aniline Chemical compound CC(C)N=NNC1=CC=C(C)C=C1 AGDYKCPGMDASQO-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WCSVJBCKWSHLCX-UHFFFAOYSA-N methyl 2-(3-sulfanylpropylsulfanyl)acetate Chemical compound COC(=O)CSCCCS WCSVJBCKWSHLCX-UHFFFAOYSA-N 0.000 description 1
- ABNUQSMSZOBPRP-XEXWXRIDSA-N methyl 2-[3-[(1r,2s,3r)-3-hydroxy-2-[(e)-3-hydroxy-4-phenylpent-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetate Chemical compound O[C@@H]1CC(=O)[C@H](SCCCSCC(=O)OC)[C@H]1\C=C\C(O)C(C)C1=CC=CC=C1 ABNUQSMSZOBPRP-XEXWXRIDSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- JLMWXJKOCRNXGG-RIYZIHGNSA-N tert-butyl-[(e)-4-iodo-1-(1-propylcyclobutyl)but-3-enoxy]-dimethylsilane Chemical compound I/C=C/CC(O[Si](C)(C)C(C)(C)C)C1(CCC)CCC1 JLMWXJKOCRNXGG-RIYZIHGNSA-N 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Paper (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Window Of Vehicle (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/851,296 US6410591B1 (en) | 2001-05-08 | 2001-05-08 | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US851296 | 2001-05-08 | ||
| PCT/US2002/014331 WO2002089813A2 (en) | 2001-05-08 | 2002-05-06 | 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60219614D1 DE60219614D1 (de) | 2007-05-31 |
| DE60219614T2 true DE60219614T2 (de) | 2007-12-27 |
Family
ID=25310439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60219614T Expired - Lifetime DE60219614T2 (de) | 2001-05-08 | 2002-05-06 | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6410591B1 (enExample) |
| EP (1) | EP1385526B1 (enExample) |
| JP (1) | JP2004529166A (enExample) |
| AT (1) | ATE359794T1 (enExample) |
| AU (1) | AU2002305416B2 (enExample) |
| CA (1) | CA2446386C (enExample) |
| DE (1) | DE60219614T2 (enExample) |
| ES (1) | ES2284872T3 (enExample) |
| WO (1) | WO2002089813A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410591B1 (en) * | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US7872045B2 (en) * | 2001-06-14 | 2011-01-18 | Allergan, Inc. | Combination therapy for glaucoma treatment |
| US20030027853A1 (en) | 2001-06-14 | 2003-02-06 | Allergan Sales, Inc. | 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US20050222094A1 (en) * | 2001-06-14 | 2005-10-06 | Burk Robert M | Treatment of inflammatory bowel disease |
| KR101077461B1 (ko) * | 2003-02-11 | 2011-10-26 | 알러간, 인코포레이티드 | 안압 강하제로서의 10,10-디알킬 프로스탄산 유도체 |
| US7179820B2 (en) * | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US7186744B2 (en) * | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| WO2006041875A1 (en) | 2004-10-06 | 2006-04-20 | Allergan, Inc. | Novel prostamides for the treatment of glaucoma and related diseases |
| US7183324B2 (en) * | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| CA2669763C (en) | 2006-11-16 | 2015-02-17 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| US8455547B2 (en) * | 2008-02-05 | 2013-06-04 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| US7732443B2 (en) * | 2008-03-18 | 2010-06-08 | Yariv Donde | Therapeutic substituted cyclopentanes |
| US7960378B2 (en) * | 2008-03-18 | 2011-06-14 | Allergan, Inc. | Therapeutic compounds |
| RU2500674C2 (ru) * | 2008-05-09 | 2013-12-10 | Аллерган, Инк. | Терапевтические соединения |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| US8859616B2 (en) * | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
| CN109072186B (zh) | 2016-03-04 | 2023-06-23 | 莱兰斯坦福初级大学评议会 | 利用前列腺素e2进行肌肉再生的组合物和方法 |
| JP7372911B2 (ja) | 2017-06-09 | 2023-11-01 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 筋肉の状態を予防または治療するための組成物および方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937265A (en) * | 1987-05-28 | 1990-06-26 | Teijin Limited | Antidiabetic method comprising 7-thiaprostaglandin E1 or its derivatives |
| JP3579448B2 (ja) * | 1993-12-29 | 2004-10-20 | 大正製薬株式会社 | プロスタグランジン誘導体、その塩およびその使用 |
| JPH09286775A (ja) * | 1996-04-24 | 1997-11-04 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
| NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
| AU2183900A (en) * | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US6545045B1 (en) * | 1998-12-24 | 2003-04-08 | Alcon Manufacturing, Ltd. | Prostaglandin E agonists for treatment of glaucoma |
| JP2001151749A (ja) * | 1999-11-24 | 2001-06-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
| US6410591B1 (en) * | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| EP1461026A2 (en) * | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
-
2001
- 2001-05-08 US US09/851,296 patent/US6410591B1/en not_active Expired - Fee Related
-
2002
- 2002-05-06 JP JP2002586948A patent/JP2004529166A/ja active Pending
- 2002-05-06 DE DE60219614T patent/DE60219614T2/de not_active Expired - Lifetime
- 2002-05-06 WO PCT/US2002/014331 patent/WO2002089813A2/en not_active Ceased
- 2002-05-06 EP EP02734233A patent/EP1385526B1/en not_active Expired - Lifetime
- 2002-05-06 CA CA2446386A patent/CA2446386C/en not_active Expired - Fee Related
- 2002-05-06 ES ES02734233T patent/ES2284872T3/es not_active Expired - Lifetime
- 2002-05-06 AU AU2002305416A patent/AU2002305416B2/en not_active Ceased
- 2002-05-06 AT AT02734233T patent/ATE359794T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002305416B2 (en) | 2008-01-10 |
| JP2004529166A (ja) | 2004-09-24 |
| WO2002089813A3 (en) | 2003-02-27 |
| WO2002089813A2 (en) | 2002-11-14 |
| ES2284872T3 (es) | 2007-11-16 |
| EP1385526A2 (en) | 2004-02-04 |
| DE60219614D1 (de) | 2007-05-31 |
| CA2446386A1 (en) | 2002-11-14 |
| US6410591B1 (en) | 2002-06-25 |
| ATE359794T1 (de) | 2007-05-15 |
| EP1385526B1 (en) | 2007-04-18 |
| CA2446386C (en) | 2011-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60219614T2 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| DE60206408T2 (de) | Omega-zykloalkyl 17-heteroaryl prostaglandin-e2-analoga als ep2-rezeptoragonisten | |
| DE69524446T2 (de) | Ep2-rezeptoragonisten als mittel zur senkung des augeninnendrucks | |
| DE69418214T2 (de) | Cyclopentan(penten)-hepten-oder heptansäuren und deren derivate als therapeutische wirkstoffe | |
| DE69714023T2 (de) | Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel | |
| DE69613693T2 (de) | 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes | |
| DE69127755T2 (de) | Okulare hypotensive 2-dekarboxyl-2-aminoalkyl-prostaglandine | |
| AU2002305416A1 (en) | 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure | |
| US6767920B2 (en) | 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure | |
| DE69430538T2 (de) | 2-azylalkyl-oder arylalenyl-cyclopentanheptan-und heptensäuren, derivate und therapeutische anwendung | |
| US6531504B2 (en) | Prostanoic acid derivatives as agents for lowering intraocular pressure | |
| AU2002316081A1 (en) | Prostanoic acid derivatives as agents for lowering intraocular pressure | |
| DE60118628T2 (de) | Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogen als ep2-rezeptor agonisten | |
| DE69710333T2 (de) | Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie | |
| DE69206262T2 (de) | Oxalon Und Hypotensive 2-Decarboxyl-2 Azylthioalkyl Prostagladin-Derivate. | |
| DE60104435T2 (de) | 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel | |
| US5328933A (en) | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues | |
| DE69112080T2 (de) | 2-decarboxyl-2-alkoxyalkyl-prostaglandine als augenbinnendrucksenkende mittel. | |
| DE69129238T2 (de) | Okulare hypotensive homo-prostaglandinderivate | |
| US5656635A (en) | 5-trans-alcohols and their use as ocular hypotensives | |
| DE69119900T2 (de) | Verwendung von Prostaglandin F3alpha als okulares Hypotensivum | |
| WO1992013836A1 (en) | 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives | |
| US6124353A (en) | Method of treating ocular hypertension with 8-epi prostaglandins | |
| US5194449A (en) | Use of prostaglandin F3α as an ocular hypotensive agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |